6I5E

X-ray structure of apo human soluble Epoxide Hydrolase C-terminal Domain (hsEH CTD)

6I5E の概要

• エントリーDOI: 10.2210/pdb6i5e/pdb
• 分子名称: Bifunctional epoxide hydrolase 2 (2 entities in total)
• 機能のキーワード: hseh ctd, apoprotein, alpha_beta hydrolase fold, hydrolase
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 79090.50

構造登録者

Abis, G.,Kopec, J.,Yue, W.W.,Conte, M.R. (登録日: 2018-11-13, 公開日: 2019-05-29, 最終更新日: 2024-01-24)

主引用文献

Abis, G.,Charles, R.L.,Kopec, J.,Yue, W.W.,Atkinson, R.A.,Bui, T.T.T.,Lynham, S.,Popova, S.,Sun, Y.B.,Fraternali, F.,Eaton, P.,Conte, M.R.
15-deoxy-Delta12,14-Prostaglandin J2inhibits human soluble epoxide hydrolase by a dual orthosteric and allosteric mechanism.
Commun Biol, 2:188-188, 2019

PubMed Abstract: Human soluble epoxide hydrolase (hsEH) is an enzyme responsible for the inactivation of bioactive epoxy fatty acids, and its inhibition is emerging as a promising therapeutical strategy to target hypertension, cardiovascular disease, pain and insulin sensitivity. Here, we uncover the molecular bases of hsEH inhibition mediated by the endogenous 15-deoxy-Δ-Prostaglandin J (15d-PGJ). Our data reveal a dual inhibitory mechanism, whereby hsEH can be inhibited by reversible docking of 15d-PGJ in the catalytic pocket, as well as by covalent locking of the same compound onto cysteine residues C423 and C522, remote to the active site. Biophysical characterisations allied with in silico investigations indicate that the covalent modification of the reactive cysteines may be part of a hitherto undiscovered allosteric regulatory mechanism of the enzyme. This study provides insights into the molecular modes of inhibition of hsEH epoxy-hydrolytic activity and paves the way for the development of new allosteric inhibitors.

PubMed: 31123712
DOI: 10.1038/s42003-019-0426-2

実験手法

X-RAY DIFFRACTION (2.6 Å)